What is the current stock price of Cytokinetics, Incorporated (CYTK)?

As of the latest market data, Cytokinetics, Incorporated (CYTK) is trading at $65.01. The stock has seen a gain of 0.65% today.

Does Cytokinetics, Incorporated (CYTK) pay a dividend?

Based on current data, Cytokinetics, Incorporated does not have a confirmed active dividend policy.

What is the market cap of Cytokinetics, Incorporated?

The current market capitalization of Cytokinetics, Incorporated (CYTK) is approximately unavailable.

CYTK

Cytokinetics, Incorporated·Healthcare

65.01

0.650%(+0.42)

Market Closed

67.12

3.246%(+2.11)

After Hours

Last Updated: — ET

52W L: $29.3152W H: $70.98

CYTK NEWS

globenewswire.com

4d ago

Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 1:30 PM Eastern Time.

defenseworld.net

Mar 28

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Brokerages

Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-one ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have issued a buy rating on the

zacks.com

Mar 26

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

globenewswire.com

Mar 18

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 13, 2026 it granted stock options to purchase an aggregate of 8,628 shares of common stock and 5,719 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in February and March 2026 as a material inducement to their employment.

defenseworld.net

Mar 17

Bamco Inc. NY Makes New Investment in Cytokinetics, Incorporated $CYTK

Bamco Inc. NY purchased a new stake in Cytokinetics, Incorporated (NASDAQ: CYTK) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 24,500 shares of the biopharmaceutical company's stock, valued at approximately $1,347,000. A number of other institutional investors

globenewswire.com

Mar 16

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations related to MYQORZO™ (aficamten) at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place March 28–30, 2026 in New Orleans, LA.

Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

498

IPO Date

2004-04-30

Beta

0.48

Websitewww.cytokinetics.com↗